Novel agents for diffuse large B-cell lymphoma

Bibliography

• Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010;60:393-408
   PubMed Web of Science ®Google Scholar
• Shenoy PJ, Malik N, Nooka A, Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer (In press)
   Google Scholar
• McKelvey EM, Gottlieb JA, Wilson HE, Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976;38:1484-93
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26
   PubMed Web of Science ®Google Scholar
• Flowers CR, Armitage JO. A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk 2010;10:414-23
   Google Scholar
• Rosenwald A, Wright G, Chan WC, The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Choi WW, Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587-94
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Sandeep D, Gene expression signatures predict survival in diffuse large B cell lymphoma following rituximab and CHOP-like chemotherapy. Blood 2007;110:209a (Abstr 348)
   Google Scholar
• Wilson WH, Dunleavy K, Pittaluga S, Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717-24
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright GW, Emre NC, Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105:13520-5
   PubMed Web of Science ®Google Scholar
• Chan WJ. Pathogenesis of diffuse large B cell lymphoma. Int J Hematol 2010;92:219-30
   PubMed Web of Science ®Google Scholar
• Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005;87:163-208
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-74
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-90
   PubMed Web of Science ®Google Scholar
• Dredge K, Horsfall R, Robinson SP, Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005;69:56-63
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6
   PubMed Web of Science ®Google Scholar
• Schafer PH, Gandhi AK, Loveland MA, Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003;305:1222-32
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005;11:5984-92
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140:36-45
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952-7
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-hodgkin's lymphoma (a-NHL): results from an International phase 2 study (CC-5013-NHL-003) [abstract]. Blood 2009;114:1676
   Google Scholar
• Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R). J Clin Oncol 2010;28: abstract 8038
   PubMed Web of Science ®Google Scholar
• Nowakowski G, LaPlant B, Habermann T, A phase I/II trial of lenalidomide and RCHOP (R2CHOP) in patients with newly diagnosed diffuse large B cell (DLBCL) and follicular grade 3 lymphoma. Am Soc Hematol Annual Meeting Abstracts 2009;114:1669
   Google Scholar
• Hideshima T, Chauhan D, Richardson P, NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6
   PubMed Web of Science ®Google Scholar
• Sunwoo JB, Chen Z, Dong G, Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-28
   PubMed Web of Science ®Google Scholar
• Cusack JC Jr, Liu R, Houston M, Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61:3535-40
   PubMed Web of Science ®Google Scholar
• Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007;13:1076-82
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein S, McDonald A, Immunohistochemical analyses for potential biomarkers of bortezomib acitivity in mantle cell lymphoma form the PINNACLE phase 2 trail. Blood 2007;110:2573
   Web of Science ®Google Scholar
• Keats JJ, Fonseca R, Chesi M, Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131-44
   PubMed Web of Science ®Google Scholar
• Furman RR, Martin P, Ruan J, Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer 2010;116:5432-9
   Google Scholar
• Ruan J, Martin P, Furman RR, Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690-7
   Google Scholar
• Ribrag V, Gisselbrecht C, Haioun C, Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA). Cancer 2009;115:4540-6
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Czuczman MS, Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-76
   PubMed Web of Science ®Google Scholar
• Demo SD, Kirk CJ, Aujay MA, Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-91
   PubMed Web of Science ®Google Scholar
• McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008;11:164-79
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-90
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Stewart AK, Vallone M, A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009;15:7085-91
   PubMed Web of Science ®Google Scholar
• Hamlin P, Aghajanian C, Younes A, First-in-human phase I study of the novel structure proteasome inhibitor NPI-0052 [abstract]. J Clin Oncol 2009;27: Suppl abstract #3516
   Web of Science ®Google Scholar
• Chauhan D, Hideshima T, Anderson KC. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer 2006;95:961-5
   PubMed Web of Science ®Google Scholar
• Soucy TA, Smith PG, Milhollen MA, An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732-6
   PubMed Web of Science ®Google Scholar
• Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009;15:3912-6
   PubMed Web of Science ®Google Scholar
• Milhollen MA, Traore T, Adams-Duffy J, MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010;116:1515-23
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005;23:9408-21
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83
   PubMed Web of Science ®Google Scholar
• Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene 2003;22:6609-20
   PubMed Web of Science ®Google Scholar
• Hwang HC, Clurman BE. Cyclin E in normal and neoplastic cell cycles. Oncogene 2005;24:2776-86
   PubMed Web of Science ®Google Scholar
• Blagden S, de Bono J. Drugging cell cycle kinases in cancer therapy. Curr Drug Targets 2005;6:325-35
   PubMed Web of Science ®Google Scholar
• Lam LT, Pickeral OK, Peng AC, Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2: RESEARCH0041
   Google Scholar
• Takada Y, Aggarwal BB. Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 2004;279:4750-9
   PubMed Web of Science ®Google Scholar
• Tay K, Shapiro GI, Disinski M, Phase I/II study of a hybrid schedule of flavopiridol in relapsed/refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2009;27:8563
   Google Scholar
• Conroy A, Stockett DE, Walker D, SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 2009;64:723-32
   PubMed Web of Science ®Google Scholar
• Misra RN, Stockett DE, Walker D, N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 2004;47:1719-28
   PubMed Web of Science ®Google Scholar
• Heath EI, Bible K, Martell RE, A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008;26:59-65
   Google Scholar
• Turner M, Schweighoffer E, Colucci F, Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today 2000;21:148-54
   PubMedGoogle Scholar
• Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science 2002;296:1641-2
   PubMed Web of Science ®Google Scholar
• Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006;6:283-94
   PubMed Web of Science ®Google Scholar
• Smith SH, Reth M. Perspectives on the nature of BCR-mediated survival signals. Mol Cell 2004;14:696-7
   PubMed Web of Science ®Google Scholar
• Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997;90:1073-83
   PubMed Web of Science ®Google Scholar
• Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004;117:787-800
   PubMed Web of Science ®Google Scholar
• Chen L, Monti S, Juszczynski P, SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008;111:2230-7
   PubMed Web of Science ®Google Scholar
• Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol 2006;176:5715-9
   PubMed Web of Science ®Google Scholar
• Benschop RJ, Cambier JC. B cell development: signal transduction by antigen receptors and their surrogates. Curr Opin Immunol 1999;11:143-51
   PubMed Web of Science ®Google Scholar
• Monti S, Savage KJ, Kutok JL, Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-61
   PubMed Web of Science ®Google Scholar
• Chen L, Juszczynski P, Takeyama K, Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood 2006;108:3428-33
   PubMed Web of Science ®Google Scholar
• Braselmann S, Taylor V, Zhao H, R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006;319:998-1008
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-18
   PubMed Web of Science ®Google Scholar
• Podolanczuk A, Lazarus AH, Crow AR, Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009;113:3154-60
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-85
   PubMed Web of Science ®Google Scholar
• de Jong D, Balague Ponz O. The molecular background of aggressive B cell lymphomas as a basis for targeted therapy. J Pathol 2011;223:274-82
   PubMed Web of Science ®Google Scholar
• Carducci MA, Musib L, Kies MS, Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24:4092-9
   PubMed Web of Science ®Google Scholar
• Su TT, Guo B, Kawakami Y, PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002;3:780-6
   PubMed Web of Science ®Google Scholar
• Shinohara H, Yasuda T, Aiba Y, PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med 2005;202:1423-31
   PubMed Web of Science ®Google Scholar
• Sommer K, Guo B, Pomerantz JL, Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity 2005;23:561-74
   PubMed Web of Science ®Google Scholar
• Rueda D, Thome M. Phosphorylation of CARMA1: the link(er) to NF-kappaB activation. Immunity 2005;23:551-3
   Google Scholar
• Yoshiji H, Kuriyama S, Ways DK, Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 1999;59:4413-8
   PubMed Web of Science ®Google Scholar
• Teicher BA, Menon K, Alvarez E, Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts. Cancer Chemother Pharmacol 2001;48:473-80
   PubMed Web of Science ®Google Scholar
• Suzuma K, Takahara N, Suzuma I, Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA 2002;99:721-6
   PubMed Web of Science ®Google Scholar
• Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 2001;10:2117-40
   PubMed Web of Science ®Google Scholar
• Balendran A, Hare GR, Kieloch A, Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett 2000;484:217-23
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR, The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-9
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Kahl BS, Vose JM, Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6
   PubMed Web of Science ®Google Scholar
• Midgley R, Kerr D. Bevacizumab–current status and future directions. Ann Oncol 2005;16:999-1004
   PubMed Web of Science ®Google Scholar
• Salmon JS, Lockhart AC, Berlin J. Anti-angiogenic treatment of gastrointestinal malignancies. Cancer Invest 2005;23:712-26
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamato M, Nakamine H, Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002;68:91-100
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34
   PubMed Web of Science ®Google Scholar
• Ganjoo KN, An CS, Robertson MJ, Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006;47:998-1005
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Unger JM, Rimsza LM, A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 2009;50:728-35
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 2010;1804:433-9
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain AR, Siraj AK, Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178-86
   PubMed Web of Science ®Google Scholar
• Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28:727-32
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
   PubMed Web of Science ®Google Scholar
• Gupta M, Ansell SM, Novak AJ, Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009;114:2926-35
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder CB, Laplant BR, A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341-7
   PubMed Web of Science ®Google Scholar
• Tobinai K, Ogura M, Maruyama D, Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. Int J Hematol 2010;92:563-70
   PubMed Web of Science ®Google Scholar
• Ramakrishnan V, Timm M, Haug JL, Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010;29:1190-202
   PubMed Web of Science ®Google Scholar